This is the authors' abstract. We don't add key points for this paper.
V600E-variant. However, there is limited evidence of the use of BRAF inhibitors in pregnancy. Hence, the purpose of this systematic review is to synthesize published reports evaluating the risk-benefit of BRAF inhibitor exposure during pregnancy.MethodsA systematic search was conducted of PubMed, Scopus, Embase, Web of Science, and CINAHL Ultimate for articles published between January 1, 1966 and June 15, 2026. Included studies were those that involved women with a cancer diagnosis who received a BRAF inhibitor while pregnant and had clinical findings of the fetus post-BRAF inhibitor treatment.ResultsIn total, 422 records were screened, yielding 7 cases of BRAF-inhibitor exposure during pregnancy. All patients presented with melanoma and vemurafenib was given in all but one case that used dabrafenib. Age of the mothers ranged from 25-37 years old. BRAF-inhibitor exposure occurred during the second trimester in 5 cases and in 1 case during the third trimester. Gestational age at delivery ranged from 26-36 weeks. The mother was alive at presentation in 2 of the 5 reported cases. Fetal adverse events occurred in 4 of the 7 cases including paroxysmal supraventricular tachycardia, intrauterine growth restriction, heart malformations, and delayed cranial ossification.ConclusionIn this systematic review, BRAF inhibitor therapy during the second or third trimester of pregnancy may be associated with viable outcomes but carry significant potential risks to the fetus. Clinicians should approach BRAF inhibitor use during pregnancy with individualized, multi-disciplinary discussions.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hermanson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: